Global reach Novotech operates a 30+ office global footprint with access to 5,000+ trial sites across Asia-Pacific, North America, and Europe, presenting a broad potential for multi-region clinical trials and site-network expansion partnerships.

Strong awards Consistent Frost & Sullivan CRO Company of the Year awards for 19 years strengthen credibility with potential clients, supporting value-based selling around reliability, quality, and proven performance.

Strategic partnerships Recent alliances with The START Center for Cancer Research and Marvel Biosciences indicate a readiness to co-develop early-phase and oncology-focused trials, signaling opportunities to cross-sell CRO services to high-growth biotech programs.

Digital trial capability Adoption of digital trial delivery through ObvioGo and a tech-enabled operations base suggests a compelling angle for clients seeking faster patient recruitment and decentralized or hybrid trial models.

Leadership momentum New CEO appointment in 2026 combined with continued large-scale collaborations and recognized market position creates a narrative for strategic engagements with mid- to large-size biotechs seeking scalable CRO partnerships.